CN108254565A - A kind of β 2-MG detection kits, method of preparation and use based on bimolecular fluorescence complementary technology - Google Patents
A kind of β 2-MG detection kits, method of preparation and use based on bimolecular fluorescence complementary technology Download PDFInfo
- Publication number
- CN108254565A CN108254565A CN201711271923.0A CN201711271923A CN108254565A CN 108254565 A CN108254565 A CN 108254565A CN 201711271923 A CN201711271923 A CN 201711271923A CN 108254565 A CN108254565 A CN 108254565A
- Authority
- CN
- China
- Prior art keywords
- fluorescin
- terminal segment
- antibody
- preparation
- couplings
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
The present invention provides a kind of 2 MG diagnostic kits of β based on bimolecular fluorescence complementary technology.The kit includes：The fluorescin N-terminal segment of anti-2 MG antibody couplings of β, the fluorescin C-terminal segment of 2 MG antibody couplings of anti-β；The invention also discloses a kind of preparation method of the 2 MG diagnostic kits of β based on bimolecular fluorescence complementary technology, this method includes：The preparation of the fluorescin N-terminal segment of anti-2 MG antibody couplings of β, the preparation of the fluorescin C-terminal segment of 2 MG antibody couplings of anti-β；Finally also disclose the application method of the kit；Kit of the present invention has many advantages, such as that easy to operate, the range of linearity is wide, specificity is good, free of cleaning, accuracy is high, it is used convenient for clinical detection, it is applied to the monitoring of kidney trouble, it can reflect renal disease symptom in time, accurate response change of illness state will then be will be widely welcomed by market and have great market value.
Description
Technical field
Contain the present invention relates to a kind of bimolecular fluorescence complementary technology for β 2-MG in ion vitro immunization diagnosis detection human body
Amount, belongs to medical diagnosis on disease detection field.
Background technology
β2-microglobulin english abbreviation is β 2-MG or BMG, is that Berggard is equal to nineteen sixty-eight first from tamm-Horsfall protein
It is separated in urine.Be by lymphocyte, blood platelet, polymorphonuclear leukocyte generate a kind of small molecule globulin, molecule matter
It is 11800 to measure, and containing 100 amino acid and a disulfide bond, is gained the name when being located at 2 zone of β when electrophoresis.β 2-MG is on cell membranes
The light chain construct of complete tissue compatibility antigen (HLA), in addition to ripe cell and placental trophoblasts, other cells contain
There are β 2-MG, be present in the surface of karyocyte.In addition to ripe cell and placental trophoblasts, other cells contain β 2-
MG is present in the surface of karyocyte.It is distributed widely in serum, urine, cerebrospinal fluid, saliva and colostrum.Due to metabolism and
The degradation of HLA after β 2-MG separation, is present in extracellular fluid, including serum, urine, saliva, cerebrospinal fluid and chest, abdomen in a free form
In chamber hydrops.
Normal human serum β 2-MG concentration is fairly constant, and range is (0.3~3.0mg/L), and β 2-MG easily pass through glomerulus
Filter membrane, but almost all is absorbed by proximal convoluted tubule in the form of pinocytosis, is degraded to amino acid being locally metabolized, normal health human urine
The synthetic ratio of middle a concentration of (0.03~0.37mg/L) normal person β 2-MG of β 2-MG and fairly constant from the burst size on cell membrane,
β 2-MG can freely be filtered from glomerulus, and 99.9% absorbs in proximal tubular, and decomposes and break in renal cells
It is bad；So the discharge of β 2-MG is very micro under normal circumstances；And many diseases, hepatitis, ephritis, rheumatoid arthritis and
Malignant tumour, immunity disease etc. can increase serum β 2-MG.
Because of β 2-MG, production rate is more constant in vivo, and only by kidney excretion daily.It is as serum creatinine and GFR
Between there is significant correlation, therefore, measuring serum β 2-MG can be as the index of glomerular filtration rate, therefore initially mainly transports
For kidney function test, start clinically to be able to extensive use, particularly have to the clinical diagnosis evaluation of urologic disease
Important value.In recent years the study found that the detection of β 2-MG to kidney trouble, malignant tumour, diabetes, hypertension and coronary disease
Diagnosis, antidiastole and the prognosis estimation of disease etc. have important references value.
The diagnostic significance of blood and urine β 2-MG have：(1) serum β 2-MG increases and to urinate β 2-MG normal, is filtered mainly due to glomerulus
Function reduction is crossed, is common in acute and chronic ephritis, renal failure etc..(2) serum β 2-MG it is normal and urinate β 2-MG raisings mainly due to
Reabsorption function is significantly damaged, and sees congenital proximal convoluted tubule functional defect, Fanconi syndrome, chronic cadium poisoning,
Wilson diseases, kidney transplantation exclusion reaction etc..(3) blood, urine β 2-MG are increased generates excessive or kidney mainly due to certain positions in vivo
Bead and renal tubule are all damaged, and are common in malignant tumour (such as primary carcinoma of liver, lung cancer, myeloma), autoimmune
Disease (such as systemic loupus erythematosus, hemolytic anemia), chronic hepatitis, diabetic nephropathy etc..The elderly also shows blood, urine β 2-
MG is increased.In addition, can also it be increased using medicines such as kanamycins, gentamicin, polymyxins.
At present, the method for common diagnosing beta 2-MG has the colloidal gold method of quick diagnosis and fluorescent immune method, enzyme-linked immunization
(ELISA), latex-enhanced turbidimetry and Magnetism particulate immuno chemistry luminescence method (CMIA).Although colloidal gold method detection speed is very fast,
Accuracy is not high, is only used for qualitative or half-quantitative detection；Fluorescent immune method sensitivity based on immunochromatography is higher, but CV
It is larger；ELISA method sensitivity is inadequate, and the operating time is long, and step is cumbersome.CMIA methods are although easy to operate compared with ELISA method, inspection
Degree of testing the speed is fast, but due to being heterogeneous reaction, and operating process needs to clean, and the repeatability of detection is not high.
To solve the above problems, if the antibody of β 2-MG, using bimolecular fluorescence complementary technology as platform, research and development can be utilized
Go out a kind of β 2-MG quick detection reagents for Diagnosis of Renal Disorders.Make it compared with existing detection reagent, there is operation side
Just the advantages that, detection is quick, high sensitivity, accuracy are good；It is applied to the monitoring of kidney trouble, kidney trouble can be improved
The accuracy rate of diagnosis.It will then be will be widely welcomed by market and there is great market value.
Invention content
For the technical problems in the prior art, the present invention provides a kind of detection that can be used for quantitatively detection β 2-MG
Kit, its method of preparation and use.
The invention is realized by the following technical scheme：
It is a kind of to prepare the method based on bimolecular fluorescence complementary technology β 2-MG detection kits, include the following steps：
1) anti-β 2-MG antibody couplings fluorescin N-terminal segment；
2) anti-β 2-MG antibody couplings fluorescin C-terminal segment；
In the above-mentioned technical solutions, the anti-β 2-MG antibody is for the monoclonal antibody of β 2-MG different epitopes or more grams
Grand antibody.
In said program, the step of the anti-β 2-MG antibody couplings fluorescin N-terminal segment in, fluorescin N-terminal piece
The mass ratio of Duan Yukang β 2-MG antibody is 1: 1-10.
In said program, the step of the anti-β 2-MG antibody couplings fluorescin C-terminal segment in, fluorescin C-terminal piece
The mass ratio of Duan Yukang β 2-MG antibody is 1: 1-10.
The prepared β 2-MG detection reagents based on bimolecular fluorescence complementary technology according to any of the above technical solution
Box.Its mainly form including：
1) the fluorescin N-terminal segment of anti-β 2-MG antibody couplings；
2) the fluorescin C-terminal segment of anti-β 2-MG antibody couplings.
The application method of kit described in any of the above technical solution, it is characterised in that：Include the following steps：
1) sample, the fluorescin N-terminal segment of anti-β 2-MG antibody couplings and anti-β 2- are added in the reacting hole of kit
The fluorescin C-terminal segment of MG antibody couplings, hybrid reaction 5-60 minutes；
2) exciting light irradiation reacting hole measures each reacting hole luminous quantity and obtains fluorescence signal value.
The reacting hole of this kit can be microwell plate, micro-fluidic reagent disc, reaction cup, reaction tube etc..
Description of the drawings
Fig. 1 is that the β 2-MG detection kit principles provided in an embodiment of the present invention based on bimolecular fluorescence complementary technology are shown
It is intended to, wherein, the anti-β 2-MG antibody of 1-, 2- bridging agents, 3- fluorescin N-terminal segments, 4- determinands (β 2-MG), the anti-β 2-MG of 5-
Antibody, 6- fluorescin C-terminal segments, 7- bridging agents.
Fig. 2 is the β 2-MG detection kit detection lines provided in an embodiment of the present invention based on bimolecular fluorescence complementary technology
Property areal map.
Fig. 3 is the β 2-MG detection kit result phases provided in an embodiment of the present invention based on bimolecular fluorescence complementary technology
Closing property compares.
Specific embodiment
Below with reference to attached drawing to the present invention the β 2-MG detection kits based on bimolecular fluorescence complementary technology, prepare and
Its application method is described in detail.
Embodiment 1
Anti- β 2-MG antibody couplings fluorescin N-terminal segment, with the segment of yellow fluorescence protein (YFP) 1-154 amino acid
For YFPN, specific implementation process is：
1) 0.1mg YFPN albumen is added in centrifuge tube, is matched with 0.05mol/L pH9.5 carbonate buffer solutions (CB)
YFPN albumen is diluted to 1mg/ml by system.
2) final concentration of 1.25% glutaraldehyde is added in draught cupboard.
3) 37 DEG C of water-bath 2h.
4) it is dialysed with desalting column Sephadex G-25 or 0.05mol/L pH9.5 CB and removes excessive glutaraldehyde.
5) the anti-β 2-MG antibody of 0.1mg is taken, 1mg/ml antibody is prepared with 0.05mol/L pH9.5 CB, by the YFPN of activation
Albumen and antibody mixing.
6) 4 DEG C, reaction is overnight.
7) it closes：50 μ l 0.2mol/L lysine solutions are added in, room temperature closing 2h to close remaining aldehyde radical, is terminated anti-
It should.
8) 4 DEG C of placement 2h.
9) polymer insoluble matter is removed by reactant by Sephadex G-200 gel columns or with 0.45 μm of filter membrane, used
0.01mol/L pH7.2 PBS dialysis purification conjugates, are diluted to required concentration before use.
Embodiment 2
Anti- β 2-MG antibody couplings fluorescin C-terminal segment, with the segment of yellow fluorescence protein (YFP) 155-238 amino acid
For YFPC, specific implementation process is：
1) 0.1mg YFPC albumen is added in centrifuge tube, is matched with 0.05mol/L pH9.5 carbonate buffer solutions (CB)
YFPC albumen is diluted to 1mg/ml by system.
2) final concentration of 1.25% glutaraldehyde is added in draught cupboard.
3) 37 DEG C of water-bath 2h.
4) it is dialysed with desalting column Sephadex G-25 or 0.05mol/L pH9.5 CB and removes excessive glutaraldehyde.
5) the anti-β 2-MG antibody of 0.1mg is taken, 1mg/ml antibody is prepared with 0.05mol/L pH9.5 CB, by the YFPC of activation
Albumen and antibody mixing.
6) 4 DEG C, reaction is overnight.
7) it closes：50 μ l 0.2mol/L lysine solutions are added in, room temperature closing 2h to close remaining aldehyde radical, is terminated anti-
It should.
8) 4 DEG C of placement 2h.
9) polymer insoluble matter is removed by reactant by Sephadex G-200 gel columns or with 0.45 μm of filter membrane, used
0.01mol/L pH7.2 PBS dialysis purification conjugates, are diluted to required concentration before use.
Embodiment 3
Kit mainly forms：
1) the fluorescin N-terminal segment of anti-β 2-MG antibody couplings；
2) the fluorescin C-terminal segment of anti-β 2-MG antibody couplings.
Embodiment 4
Kit application method, includes the following steps：
1) sample, the fluorescin N-terminal segment of anti-β 2-MG antibody couplings and anti-β 2- are added in the reacting hole of kit
The fluorescin C-terminal segment of MG antibody couplings, hybrid reaction 5-60 minutes；
2) exciting light irradiation reacting hole measures each reacting hole luminous quantity and obtains fluorescence signal value.
The reacting hole of this kit can be microwell plate, micro-fluidic reagent disc, reaction cup, reaction tube etc..
Embodiment 5
Kit method evaluation of the present invention：
It is 1. linear
Compound concentration is 0 μ g/ml, the β 2-MG of 1.25 μ g/ml, 2.5 μ g/ml FEU, 5 μ g/ml, 10 μ g/ml, 20 μ g/ml
Standard solution.20 μ l standard items, the fluorescin N-terminal for adding in the anti-β 2-MG antibody couplings of 50 μ l are separately added into reacting hole
Segment adds in the fluorescin C-terminal segment of the anti-β 2-MG antibody couplings of 50 μ l, and 37 DEG C incubate 10 minutes.After incubation, exciting light shines
Reacting hole is penetrated, each reacting hole luminous quantity is measured and obtains fluorescence signal value.
Using fluorescence signal value as ordinate, standard concentration is abscissa, draws standard working curve (see attached drawing 2).
2. accuracy
Recovery test：It is added in the serum specimen of normal person with known quantity β 2-MG standard items, measures concentration after adding in
Value is compared with the theoretical value added in, calculates the rate of recovery of β 2-MG.Testing result is as follows：
| Sample number | Add in β 2-MG concentration (μ g/ml) | Measure the concentration (μ g/ml) of β 2-MG | The rate of recovery (%) |
| 1 | 1.2 | 1.1 | 91.6 |
| 2 | 2.6 | 2.5 | 96.2 |
| 3 | 12.5 | 12.3 | 98.4 |
| 4 | 19.3 | 18.7 | 97.2 |
3. precision
Choose the sample of 3 parts of various concentrations, respectively duplicate measurements 20 times according to the method described in the present invention.According to 20 times
Measurement result calculates average deviation CV values.
4. sensitivity for analysis
The definition of sensitivity for analysis is：Refer to the amount that can be distinguished statistically with zero-dose.It is repeated 20 times measurement
Zero-dose point, calculates its average value (X) and standard deviation (SD), and the concentration value with the calculating of X+2SD is the analysis of the kit
Sensitivity.The sensitivity for analysis of kit of the present invention is 0.05 μ g/ml.
5. anti-interference
The immunological assay reagents based on bimolecular fluorescence complementary technology of the present invention are detected in interference substance (haemolysis, height
Blood fat, high bilirubin) in the presence of detect sample accuracy.Hemoglobin solutions are taken respectively and are added to β 2- in right amount
In MG positive serum samples, the content for making hemoglobin in serum is respectively 0.5mg/ml, 1.0mg/ml.By triglycerides solution
Take and be added in β 2-MG positive serum samples in right amount respectively, the content for making Triglycerides in Serum be respectively 0.5mg/ml,
1.0mg/ml.Bilirubin solution is taken respectively and is added in β 2-MG positive serum samples in right amount, makes the content of serum mesobilirubin
Respectively 25 μ g/ml, 50 μ g/ml.The β 2-MG positive samples for adding hemoglobin, triglycerides and bilirubin are surveyed
It is fixed.Using the ratio of theoretical concentration and measured concentration as the rate of recovery, the rate of recovery is between 98.1%-104.3%.Show based on double
The β 2-MG reagents of molecular fluorescence complementary technology are not done when detecting serum sample by hemoglobin, triglycerides, bilirubin
It disturbs.
6. correlation
As shown in figure 3, it is with the correlation of Landau kit：Y=1.006x+0.089, R2=0.999.
The present invention is compared with existing method and product, and with detection sensitivity height, specificity is good, cost is relatively low, to detection
The advantages of instrument requirements are low.
The above description is merely a specific embodiment, but protection scope of the present invention is not limited thereto, any
Those familiar with the art disclosed herein technical scope in, the change or replacement that can readily occur in, all
It is covered by the protection scope of the present invention.
Claims (7)
1. a kind of β 2-MG detection kits, method of preparation and use based on bimolecular fluorescence complementary technology, it is characterised in that：
1) kit mainly forms：The fluorescence of the fluorescin N-terminal segment of anti-β 2-MG antibody couplings and anti-β 2-MG antibody couplings
PROTEIN C end fragment；
2) application method：In the reacting hole of kit add in sample, anti-β 2-MG antibody couplings fluorescin N-terminal segment and
The fluorescin C-terminal segment of anti-β 2-MG antibody couplings, hybrid reaction 5-60 minutes；
3) detection method：Exciting light irradiates reacting hole, measures each reacting hole luminous quantity and obtains fluorescence signal value.
2. a kind of preparation method of the β 2-MG detection kits based on bimolecular fluorescence complementary technology, which is characterized in that including such as
Lower step：
1) preparation of anti-β 2-MG antibody couplings fluorescin N-terminal segment；
2) preparation of anti-β 2-MG antibody couplings fluorescin C-terminal segment.
3. anti-β 2-MG antibody according to claim 1 is the monoclonal antibody or Anti-TNF-α for β 2-MG different epitopes
Body.
4. fluorescin according to claim 1, including but not limited to green fluorescent protein, blue fluorescent protein, cyan
Fluorescin, yellow fluorescence protein, red fluorescent protein.
5. side prepared by a kind of β 2-MG detection kits based on bimolecular fluorescence complementary technology according to claim 2
Method, which is characterized in that in the anti-β 2-MG antibody couplings fluorescin N-terminal segment step, fluorescin N-terminal segment and β 2-
The mass ratio of MG antibody is 1: 1-10.
6. method prepared by the β 2-MG detection kits according to claim 2 based on bimolecular fluorescence complementary technology,
It is characterized in that, in the anti-β 2-MG antibody couplings fluorescin C-terminal segment step, fluorescin C-terminal segment resists with β 2-MG
The mass ratio of body is 1: 1-10.
7. reacting hole according to claim 1, including but not limited to microwell plate, micro-fluidic reagent disc, reaction cup, reaction
Pipe.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711271923.0A CN108254565A (en) | 2017-11-27 | 2017-11-27 | A kind of β 2-MG detection kits, method of preparation and use based on bimolecular fluorescence complementary technology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711271923.0A CN108254565A (en) | 2017-11-27 | 2017-11-27 | A kind of β 2-MG detection kits, method of preparation and use based on bimolecular fluorescence complementary technology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108254565A true CN108254565A (en) | 2018-07-06 |
Family
ID=62721030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711271923.0A Pending CN108254565A (en) | 2017-11-27 | 2017-11-27 | A kind of β 2-MG detection kits, method of preparation and use based on bimolecular fluorescence complementary technology |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108254565A (en) |
-
2017
- 2017-11-27 CN CN201711271923.0A patent/CN108254565A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| CLIFF I. STAINS, ET AL.: "A General Approach for Receptor and Antibody-Targeted Detection of Native Proteins Utilizing Split-Luciferase Reassembly", 《ACS CHEMICAL BIOLOGY》 * |
| 王云龙等: "用于定量ELISA方法的抗人β2微球蛋白单克隆抗体的制备及鉴定", 《免疫学杂志》 * |
| 黄欣媛等: "蛋白片段互补分析技术研究进展", 《中国生物工程杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5963900B2 (en) | Test method and test agent for malignant lymphoma by autotaxin measurement | |
| JP5554247B2 (en) | Method for measuring cystatin C in human body fluid | |
| CN110361547B (en) | Reagent for chemiluminescence quantitative detection of fecal occult blood, detection method thereof and application of reagent in detection of lower digestive tract health | |
| CN113176411B (en) | Biomarker for detecting novel coronavirus infection by saliva and application thereof | |
| US11579146B2 (en) | Detection of haptoglobin for gastrointestinal cancer determination | |
| CN108254565A (en) | A kind of β 2-MG detection kits, method of preparation and use based on bimolecular fluorescence complementary technology | |
| CN108267594A (en) | A kind of ST2 detection kits, method of preparation and use based on bimolecular fluorescence complementary technology | |
| JP3569577B2 (en) | Kit for differential diagnosis of kidney and urinary tract diseases | |
| CN108254567A (en) | A kind of NGAL detection kits, method of preparation and use based on bimolecular fluorescence complementary technology | |
| JP2000193662A (en) | Measuring reagent for cystatin c in urine, diagnostic method and kit | |
| CN206804667U (en) | A kind of multi objective time-resolved fluoroimmunoassay for renal failure Quantitative detection chromatographs kit | |
| US8697368B2 (en) | Diagnostic marker for lung cancer comprising HPαR as active ingredient | |
| CN108226529A (en) | A kind of NT-proBNP detection kits, method of preparation and use based on bimolecular fluorescence complementary technology | |
| CN108387733A (en) | A kind of mALB detection kits, method of preparation and use based on bimolecular fluorescence complementary technology | |
| CN108226519A (en) | A kind of RBP detection kits, method of preparation and use based on bimolecular fluorescence complementary technology | |
| CN108226522A (en) | A kind of Cys C detection kits, method of preparation and use based on bimolecular fluorescence complementary technology | |
| CN117110613A (en) | Diagnostic kit and application of LMWK-Fc in preparation of liver fibrosis diagnostic reagent | |
| JP7457367B2 (en) | Method and kit for determining the possibility of developing IgA nephropathy | |
| EP3816629B1 (en) | Kit for tracking and diagnosing degree of progressive chronic hepatitis and liver fibrosis by measuring asialo a1-acid glycoprotein as hepatocellular injury marker and use thereof | |
| CN108226526A (en) | A kind of SAA detection kits, method of preparation and use based on bimolecular fluorescence complementary technology | |
| JP2018066631A (en) | Method for inspecting progress level of nash and nafld and method for inspecting inflammation disease or cancer | |
| WO2013067979A1 (en) | Method for determination of the concentration of uromodulin in serum and it's use as a serologic marker for the diagnosis of nephropathy | |
| CN108226107A (en) | A kind of BNP detection kits, method of preparation and use based on bimolecular fluorescence complementary technology | |
| CN108226521A (en) | A kind of H-FABP detection kits, method of preparation and use based on bimolecular fluorescence complementary technology | |
| CN108226524A (en) | A kind of cTnT detection kits, method of preparation and use based on bimolecular fluorescence complementary technology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180706 |
|
| WD01 | Invention patent application deemed withdrawn after publication |